查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2024479

荷爾蒙避孕藥市場報告：按產品、荷爾蒙、年齡層、最終用戶和地區分類（2026-2034 年）

Hormonal Contraceptive Market Report by Product (Oral Contraceptive Pills, Intrauterine Device, Injectable Birth Control, Vaginal Rings, and Others), Hormone, Age Group, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球荷爾蒙避孕藥市場規模達200億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到272億美元，2026年至2034年的複合年成長率為3.34%。該市場正穩步成長，其促進因素包括全球對生殖健康和計劃生育意識的提高、女性賦權的進步（尤其是在發展中地區）以及全球範圍內避孕藥具的接受度和使用率的提高。

荷爾蒙避孕藥市場趨勢：

全球對生殖健康的認知與教育

全球範圍內荷爾蒙避孕藥的廣泛使用很大程度上取決於人們對生殖健康的認知和教育程度的提高。各國政府和相關國際組織，例如世界衛生組織（世衛組織），一直持續推廣透過安全有效地使用避孕藥具來實現計劃生育的理念和益處。根據世衛組織統計，截至2021年，全球育齡婦女達19億，其中11億需要計劃生育服務。在這些婦女中，8.74億人使用了現代避孕方法，而1.64億人的避孕需求未被滿足。因此，這對荷爾蒙避孕藥市場的收入產生了顯著影響。具體而言，針對男女的大規模全球宣傳活動正在普及有關控制懷孕能力以及有效遏制人口快速成長的方法的資訊。此外，針對青少年和青年人的眾多教育計畫正在實施，為他們未來做出明智的計劃生育決策奠定了基礎。這些教育舉措只有與醫療保健服務和諮詢相結合才能有效，使人們能夠比較和考慮不同的荷爾蒙避孕方法。在這方面，一個全面的全球教育和醫療保健計劃對於這些產品在全球範圍內的普及至關重要。

技術進步與產品創新

新型高效荷爾蒙避孕藥的研發正在革新這一領域，同時也提升了荷爾蒙避孕藥市場的價值。近期，一種突破性的超低劑量配方－含有20微克炔雌醇（EE）和3毫克二烯苯乙烯（DRSP）的24/4週期避孕藥（優思明；拜耳公司）上市。其有效性與傳統複方口服避孕藥（COC）相當甚至更優，且出血模式在可接受範圍內。此外，藥物傳遞系統的進步也使得產品更加可靠、易於管理且副作用更少。長效避孕藥和子宮內避孕器（IUD）的改進，例如降低健康風險和延長使用期限，滿足了消費者對便利性和生活方式適應性的日益成長的需求。此外，這些進步透過改善消費者體驗和提高依從性，擴大了市場，增加了女性使用和繼續使用避孕措施的可能性。此外，避孕產品技術的創新正利用消費者日益成長的興趣、產品供應的增加和市場選擇的多樣化，推出更先進的技術。因此，激素類避孕藥市場前景光明。

計劃生育政策和資金

政府的支持政策和對計劃生育項目的投入增加正在推動荷爾蒙避孕藥市場的成長。世界各國政府，特別是開發中國家，正在透過政策使避孕措施惠及民眾，作為公共衛生和婦女賦權措施的一部分。這些政策降低了避孕成本，使生殖健康服務更加全面、人人可及，並將避孕教育納入公共衛生宣傳活動。此外，國際聯盟和組織也為服務不足地區的生殖健康服務提供資金。所有這些措施都旨在降低成本，並鼓勵人們獲得避孕服務。保障民眾便捷、經濟地取得荷爾蒙避孕藥的政策有助於滿足公共衛生需求和其他社會經濟目標。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球荷爾蒙避孕藥市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依產品分類

  • 口服避孕藥
  • 子宮內避孕器（IUD）
  • 注射式避孕藥
  • 避孕環
  • 其他

第7章 市場區隔：依激素類分類

  • 僅含黃體素的避孕藥
  • 荷爾蒙避孕藥

第8章 市場區隔：依年齡層別分類

  • 15-24歲
  • 25-34歲
  • 35-44歲
  • 44歲或以上

第9章 市場區隔：依最終用戶分類

  • 醫院和診所
  • 居家照護
  • 門診手術中心
  • 其他

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Afaxys Inc.
    • Agile Therapeutics Inc.
    • Allergan Inc.（AbbVie Inc.）
    • Bayer AG
    • Cipla Limited
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Piramal Group
    • Teva Pharmaceutical Industries Ltd
Product Code: SR112026A4403

The global hormonal contraceptive market size reached USD 20.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 27.2 Billion by 2034, exhibiting a growth rate (CAGR) of 3.34% during 2026-2034. The market is experiencing steady growth driven by global awareness of reproductive health and family planning, the rising empowerment of women, particularly in developing regions, and the growing acceptance and use of contraceptives across the globe.

HORMONAL CONTRACEPTIVE MARKET ANALYSIS:

  • Major Market Drivers: The demand for hormonal contraceptives is driven by family planning requirements and acceptance across the globe. The various governments and non-governmental organizations that solely try to reduce the rate of unplanned pregnancies are leading to the growth of this market.
  • Key Market Trends: According to the hormonal contraceptive market forecast, the recent trend that will have a major impact on this market is the increasing consumption of long-acting reversible contraceptives including IUDs and implants on account of being more effective and longer action period.
  • Geographical Trends: North America and Western Europe majorly lead in hormonal contraceptive usage due to high awareness levels, income, and healthcare facilities. On the contrary, Asia Pacific is anticipated to grow fastest due to urbanization, healthcare expenditure, and lifestyle factors.
  • Competitive Landscape: According to the hormonal contraceptive market research, the hormonal contraceptives market has several big pharmaceutical companies with extensive product portfolios and distribution networks. Both small and large companies are increasing their budgetary allocation to research and development (R&D) activities to develop new drugs with minimal side effects while maintaining consumer convenience.
  • Challenges and Opportunities: While the existence of cultural resistance and regulatory hurdles in various geographical areas constrain market growth, there remain multiple opportunities to invest in personalized contraceptive solutions and focus on unaddressed emerging markets with an increase in female employment.

HORMONAL CONTRACEPTIVE MARKET TRENDS:

Increasing global awareness and education on reproductive health

The extensive utilization of hormonal contraceptives on a global scale is largely dependent on increased awareness and education about reproductive health. Governments and relevant international organizations, such as the World Health Organization, continuously promote the concept and advantages of family planning through safe and effective contraceptive use. According to the World Health Organization, there were 1.9 billion women of reproductive age worldwide in 2021, 1.1 billion of whom need family planning. Of these, 874 million are using modern contraceptive methods, and there are 164 million women with an unmet need for contraception. Thus, this is significantly influencing the hormonal contraceptive market revenue. Specifically, extensive global campaigns target both women and men, informing them about their ability to control pregnancies and effective ways to reduce rapid population growth. Moreover, numerous educational programs targeting teens and young individuals have been rolled out to lay the groundwork for well-informed family planning decisions later in life. These educational initiatives are only effective when complemented by access to healthcare services and consultations that enable individuals to differentiate among various hormonal contraceptive methods. In this regard, comprehensive global educational and health programs are indispensable in ensuring these products are taken up in different regions.

Technological advancements and product innovation

The development of new and better hormonal contraceptive options that revolutionize the area also propels hormonal contraceptive market value. Recently, a novel ultra-low-dose preparation of 20 μg EE and 3 mg DRSP has been marketed in a 24/4 regimen (Yaz; Bayer AG). The efficacy is similar to, if not better than, older COCs, and the bleeding pattern is acceptable. Additionally, drug delivery system development is resulting in more reliable items that are simpler to manage and produce fewer side effects. Extended-cycle pills and improvements to intrauterine devices, such as fewer health hazards and a longer period of utilization, respectively, all address the increasing need for consumer convenience and lifestyle compatibility. In addition, such advancements enhance the consumer experience and compliance, resulting in an expanded market since women are more likely to use and resume contraceptive use. In addition, innovations in contraceptive product technologies take advantage of consumers' acquired interest and adoption and market choice to introduce more refined technologies. Therefore, this is creating a positive hormonal contraceptive market outlook.

Policy initiatives and funding for family planning

Policies, such as supportive government policies and increased funding for family planning programs, facilitate the hormonal contraceptive market growth. Several governments in various regions, particularly in developing countries, have passed policies to ensure that individuals have access to contraceptives as part of public health and women's empowerment measures. These policies lower the cost of contraceptives, make reproductive health services comprehensive and available to everyone, and incorporate contraceptive education in public health campaigns. Furthermore, global consortia and institutions offer funding to help underserved areas access reproductive health services. All these measures seek to reduce the cost and convince individuals to get contraceptives. Policies that guarantee easy and low-priced access to hormonal contraceptives help to meet public health needs and other socio-economic targets.

HORMONAL CONTRACEPTIVE MARKET SEGMENTATION :

Breakup by Product:

  • Oral Contraceptive Pills
  • Intrauterine Device (IUD)
  • Injectable Birth Control
  • Vaginal Rings
  • Others

Oral contraceptive pills account for the majority of the hormonal contraceptive market share

Oral contraceptive pills (OCPs) continue to lead the hormonal contraceptive market as the largest product segment due to their unmatched combination of efficacy, convenience, and availability. The hormonal contraceptive market overview suggests that pills are the most common contraceptive method worldwide due to their safety, which secures predictable and reliable family planning. In addition to their reliability, the market for these products is diversified by the variability of formulations, with pills available in combined and progestin-only versions that reflect medical and consumer preferences. Moreover, the market tendency is determined by the price of OCPs in comparison with other long-term hormone-conjugated contraceptives, and the ease of documentation based on the long history of using OCPs that, despite the side effects, remain safe. In confluence with this, the segment is still developing, and many new options have been and continue to be developed to reduce the side effects and enhance the safety and comfort of hormonal formulations. Overall, contraceptive OCPs remain the premise of reproductive health for women worldwide.

Breakup by Hormone:

  • Progestin-only Contraceptive
  • Combined Hormonal Contraceptive

Combined hormonal contraceptive holds the largest share of the industry

The hormone sub-segment is dominated by combined hormonal contraceptives (CHCs). The main factor contributing to the segment's high share is their very high contraceptive efficacy combined with significant health benefits. Among the beneficial effects, it is worth mentioning the guaranteed duration of the menstrual cycle and the severity of menstruation, the prevention of ovarian cysts, and the significant reduction in the risk of endometrial cancer. CHCs are available in the form of pills, vaginal rings, and patches, giving users an additional choice of the form of administration that is most convenient for them. Thus, CHCs are an attractive option for a wide range of users due to their great flexibility and additional health benefits. Among the concerns, some clinicians mention the risk of mood disorders and the likelihood of weight gain. However, ongoing improvements aim to decrease the risk of these side effects, enhancing user satisfaction and adherence.

Breakup by Age Group:

  • 15-24 Years
  • 25-34 Years
  • 35-44 Years
  • Above 44 Years

15-24 years represents the leading market segment

The group of 15-24 years stands out as the largest segment of hormonal contraceptive users, based on identified trends in demographic distribution and social peculiarities. This age range usually refers to late adolescence and young adulthood, a period when individuals are most active in exploring and utilizing contraceptive options as part of their sexual and reproductive health management routines. In addition, the segment's considerable growth is driven by increased sexual activity among adolescents and young individuals, supported by broad educational programs that teach safe sex and promote the avoidance of unplanned pregnancies. Thus, this is also positively influencing the hormonal contraceptive market statistics. Educational institutions, healthcare providers, and community organizations pay special attention to this age group, conducting various outreach activities and consultations to make information about different methods of contraception more accessible. Similarly, the desire to build a career or complete education before starting a family also encourages these young individuals to seek adequate, secure, and reliable contraceptive options, contributing significantly to the strong representation of this submarket.

Breakup by End User:

  • Hospitals and Clinics
  • Homecare
  • Ambulatory Surgical Centers
  • Others

Homecare exhibits a clear dominance in the market

The leading end-user in the hormonal contraceptive market is the homecare segment, driven by the convenience and privacy it offers. Given the current trend of consumers demanding to make their healthcare decisions from the comfort of their homes, the demand for products that can be self-administered was bound to increase. This trend is further facilitated by the fact that contraceptives have become more attainable than ever before. Oral pills, transdermal patches, and vaginal rings, for example, can now be utilized without anyone's help and are readily available on the market in most parts of the world. According to the hormonal contraceptive market analysis, many online platforms and telehealth services make access to these products easy, enhancing the appeal of managing contraceptive needs at home. Furthermore, the homecare trend corresponds to the overall developments in consumer-centered healthcare, whereby individuals are seeking optimal levels of convenience, confidentiality, and autonomy in attending to their health needs. These factors have significantly altered the dynamics within the hormonal contraceptive market.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest hormonal contraceptive market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for hormonal contraceptive.

Geographically, North America is the leading market for hormonal contraceptives globally due to the region's well-developed healthcare infrastructure, high awareness about contraceptive types, and strong government support. There are also several leading pharmaceutical companies in North America investing in the development of more convenient, effective, and safe contraceptives. At the same time, Americans are the most developed in terms of the culture of taking care of their health and they prefer to "swallow" an oral agent in advance rather than an intrauterine spiral. Additionally, many types of contraceptives are covered by insurance, including under policies, which enhance accessibility. Numerous educational programs provided by public and private organizations also inform about the benefits of using contraceptives. This comprehensive support ensures that North America is not only a large market but also a leading region in the global hormonal contraceptive space.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the hormonal contraceptive industry include:

  • Afaxys Inc.
  • Agile Therapeutics Inc.
  • Allergan Inc. (AbbVie Inc.)
  • Bayer AG
  • Cipla Limited
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Piramal Group
  • Teva Pharmaceutical Industries Ltd.

The major players in the hormonal contraceptive market are committed to funding research and enhancing the efficacy and safety of their products. They consistently reduce side effects and increase user convenience to gain market acceptance and keep quality leadership. Furthermore, firms including Bayer AG, Pfizer, and Merck & Co. want to extend their global footprint through acquisitions and alliances in developing countries, where the hormonal contraceptive demand is currently higher. Additionally, manufacturers frequently promote hormonal contraception and educate more women about the advantages associated. These developments support development goals while aiding more comprehensive public health policy goals.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How has the global hormonal contraceptive market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global hormonal contraceptive market?
  • What is the impact of each driver, restraint, and opportunity on the global hormonal contraceptive market?
  • What are the key regional markets?
  • Which countries represent the most attractive hormonal contraceptive market?
  • What is the breakup of the market based on the product?
  • Which is the most attractive product in the hormonal contraceptive market?
  • What is the breakup of the market based on the hormone?
  • Which is the most attractive hormone in the hormonal contraceptive market?
  • What is the breakup of the market based on the age group?
  • Which is the most attractive age group in the hormonal contraceptive market?
  • What is the breakup of the market based on the end user?
  • Which is the most attractive end user in the hormonal contraceptive market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global hormonal contraceptive market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hormonal Contraceptive Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Oral Contraceptive Pills
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Intrauterine Device (IUD)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Injectable Birth Control
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Vaginal Rings
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Hormone

  • 7.1 Progestin-only Contraceptive
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Combined Hormonal Contraceptive
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Age Group

  • 8.1 15-24 Years
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 25-34 Years
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 35-44 Years
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Above 44 Years
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Homecare
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Ambulatory Surgical Centers
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Afaxys Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Agile Therapeutics Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Allergan Inc. (AbbVie Inc.)
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Bayer AG
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Cipla Limited
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Johnson & Johnson
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Merck & Co. Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Pfizer Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Piramal Group
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
    • 15.3.10 Teva Pharmaceutical Industries Ltd
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hormonal Contraceptive Market: Major Drivers and Challenges
  • Figure 2: Global: Hormonal Contraceptive Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Hormonal Contraceptive Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Hormonal Contraceptive Market: Breakup by Product (in %), 2025
  • Figure 5: Global: Hormonal Contraceptive Market: Breakup by Hormone (in %), 2025
  • Figure 6: Global: Hormonal Contraceptive Market: Breakup by Age Group (in %), 2025
  • Figure 7: Global: Hormonal Contraceptive Market: Breakup by End User (in %), 2025
  • Figure 8: Global: Hormonal Contraceptive Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Hormonal Contraceptive (Oral Contraceptive Pills) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Hormonal Contraceptive (Oral Contraceptive Pills) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Hormonal Contraceptive (Intrauterine Device-IUD) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Hormonal Contraceptive (Intrauterine Device-IUD) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Hormonal Contraceptive (Injectable Birth Control) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Hormonal Contraceptive (Injectable Birth Control) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Hormonal Contraceptive (Vaginal Rings) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Hormonal Contraceptive (Vaginal Rings) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Hormonal Contraceptive (Other Products) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Hormonal Contraceptive (Other Products) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Hormonal Contraceptive (Progestin-only Contraceptive) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Hormonal Contraceptive (Progestin-only Contraceptive) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Hormonal Contraceptive (Combined Hormonal Contraceptive) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Hormonal Contraceptive (Combined Hormonal Contraceptive) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Hormonal Contraceptive (15-24 Years) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Hormonal Contraceptive (15-24 Years) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Hormonal Contraceptive (25-34 Years) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Hormonal Contraceptive (25-34 Years) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Hormonal Contraceptive (35-44 Years) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Hormonal Contraceptive (35-44 Years) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Hormonal Contraceptive (Above 44 Years) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Hormonal Contraceptive (Above 44 Years) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Hormonal Contraceptive (Hospitals and Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Hormonal Contraceptive (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Hormonal Contraceptive (Homecare) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Hormonal Contraceptive (Homecare) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Hormonal Contraceptive (Ambulatory Surgical Centers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Hormonal Contraceptive (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Global: Hormonal Contraceptive (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Global: Hormonal Contraceptive (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: North America: Hormonal Contraceptive Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: North America: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: United States: Hormonal Contraceptive Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: United States: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Canada: Hormonal Contraceptive Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Canada: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Asia-Pacific: Hormonal Contraceptive Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Asia-Pacific: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: China: Hormonal Contraceptive Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: China: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Japan: Hormonal Contraceptive Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Japan: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: India: Hormonal Contraceptive Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: India: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: South Korea: Hormonal Contraceptive Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: South Korea: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Australia: Hormonal Contraceptive Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Australia: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Indonesia: Hormonal Contraceptive Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Indonesia: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Others: Hormonal Contraceptive Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Others: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Europe: Hormonal Contraceptive Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Europe: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Germany: Hormonal Contraceptive Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Germany: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: France: Hormonal Contraceptive Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: France: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: United Kingdom: Hormonal Contraceptive Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: United Kingdom: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Italy: Hormonal Contraceptive Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Italy: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Spain: Hormonal Contraceptive Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Spain: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Russia: Hormonal Contraceptive Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Russia: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Others: Hormonal Contraceptive Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Others: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Latin America: Hormonal Contraceptive Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Latin America: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Brazil: Hormonal Contraceptive Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Brazil: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Mexico: Hormonal Contraceptive Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Mexico: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Others: Hormonal Contraceptive Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 84: Others: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 85: Middle East and Africa: Hormonal Contraceptive Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 86: Middle East and Africa: Hormonal Contraceptive Market: Breakup by Country (in %), 2025
  • Figure 87: Middle East and Africa: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 88: Global: Hormonal Contraceptive Industry: SWOT Analysis
  • Figure 89: Global: Hormonal Contraceptive Industry: Value Chain Analysis
  • Figure 90: Global: Hormonal Contraceptive Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hormonal Contraceptive Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Hormonal Contraceptive Market Forecast: Breakup by Product (in Million USD), 2026-2034
  • Table 3: Global: Hormonal Contraceptive Market Forecast: Breakup by Hormone (in Million USD), 2026-2034
  • Table 4: Global: Hormonal Contraceptive Market Forecast: Breakup by Age Group (in Million USD), 2026-2034
  • Table 5: Global: Hormonal Contraceptive Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 6: Global: Hormonal Contraceptive Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Hormonal Contraceptive Market: Competitive Structure
  • Table 8: Global: Hormonal Contraceptive Market: Key Players